Energy Specific Far Infrared Radiation Treatment for AIDS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00574522|
Recruitment Status : Unknown
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : December 17, 2007
Last Update Posted : August 17, 2009
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Radiation: Far infrared||Phase 1|
Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans. The late stage of the condition leaves individuals prone to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to slow the virus' progression, there is no known cure.
The investigators are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of CD4+ T cells and other killer cells to fight and destroy the human immunodeficiency virus.
The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 20μm wavelength) on HIV/AIDS.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS|
|Study Start Date :||February 2008|
|Primary Completion Date :||August 2009|
|Estimated Study Completion Date :||November 2009|
Infrared Radiation, wavelength between 5 and 20 microns
Radiation: Far infrared
Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
- The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS. [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00574522
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|